These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. Ortiz A; Abiose A; Bichet DG; Cabrera G; Charrow J; Germain DP; Hopkin RJ; Jovanovic A; Linhart A; Maruti SS; Mauer M; Oliveira JP; Patel MR; Politei J; Waldek S; Wanner C; Yoo HW; Warnock DG J Med Genet; 2016 Jul; 53(7):495-502. PubMed ID: 26993266 [TBL] [Abstract][Full Text] [Related]
24. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience. Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283 [TBL] [Abstract][Full Text] [Related]
25. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta. Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330 [No Abstract] [Full Text] [Related]
26. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Warnock DG; Ortiz A; Mauer M; Linthorst GE; Oliveira JP; Serra AL; Maródi L; Mignani R; Vujkovac B; Beitner-Johnson D; Lemay R; Cole JA; Svarstad E; Waldek S; Germain DP; Wanner C; Nephrol Dial Transplant; 2012 Mar; 27(3):1042-9. PubMed ID: 21804088 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of enzyme replacement therapy in Fabry disease. Barbey F; Hayoz D; Widmer U; Burnier M Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):277-86. PubMed ID: 15320778 [TBL] [Abstract][Full Text] [Related]
28. Enzyme replacement therapy for Fabry disease, an inherited nephropathy. Desnick RJ; Banikazemi M; Wasserstein M Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797 [TBL] [Abstract][Full Text] [Related]
29. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478 [TBL] [Abstract][Full Text] [Related]
30. [Development of an orphan drug to treat a genetic disease: the paradigm of agalsidase beta]. Germain DP; Benistan K Presse Med; 2007 Mar; 36 Spec No 1():1S69-75. PubMed ID: 17546772 [TBL] [Abstract][Full Text] [Related]
31. Enzyme replacement therapy and Fabry kidney disease: quo vadis? Warnock DG J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046 [No Abstract] [Full Text] [Related]
33. Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: A case report. Germain DP; Bruneval P; Tran TC; Balouet P; Richalet B; Benistan K Eur J Med Genet; 2010; 53(2):111-2. PubMed ID: 20045092 [TBL] [Abstract][Full Text] [Related]
34. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E Nephron; 2015; 129(1):16-21. PubMed ID: 25531941 [TBL] [Abstract][Full Text] [Related]